Business Description
Alto Neuroscience Inc
NAICS : 541713
SIC : 2836
ISIN : US02157Q1094
Description
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.83 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.3 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.44 | |||||
| 9-Day RSI | 54.31 | |||||
| 14-Day RSI | 44.05 | |||||
| 6-1 Month Momentum % | -58.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.09 | |||||
| Quick Ratio | 13.09 | |||||
| Cash Ratio | 12.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -126.42 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -70.89 | |||||
| ROA % | -38.88 | |||||
| ROIC % | -1418.74 | |||||
| ROC (Joel Greenblatt) % | -2212.4 | |||||
| ROCE % | -40.31 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.67 | |||||
| Price-to-Tangible-Book | 0.67 | |||||
| EV-to-EBIT | 1.02 | |||||
| EV-to-EBITDA | 1.03 | |||||
| EV-to-FCF | 1.19 | |||||
| Price-to-Net-Current-Asset-Value | 0.72 | |||||
| Price-to-Net-Cash | 0.73 | |||||
| Earnings Yield (Greenblatt) % | 98.04 | |||||
| FCF Yield % | -43.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:ANRO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alto Neuroscience Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.419 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 44.05 | ||
| 14-Day ATR ($) | 0.339952 | ||
| 20-Day SMA ($) | 3.9885 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 3.56 - 24 | ||
| Shares Outstanding (Mil) | 26.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alto Neuroscience Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alto Neuroscience Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alto Neuroscience Inc Frequently Asked Questions
What is Alto Neuroscience Inc(ANRO)'s stock price today?
The current price of ANRO is $4.32. The 52 week high of ANRO is $24.00 and 52 week low is $3.56.
When is next earnings date of Alto Neuroscience Inc(ANRO)?
The next earnings date of Alto Neuroscience Inc(ANRO) is 2025-02-28 Est..
Does Alto Neuroscience Inc(ANRO) pay dividends? If so, how much?
Alto Neuroscience Inc(ANRO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers